To include your compound in the COVID-19 Resource Center, submit it here.

Syros falls on Phase II AML, MDS data

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) lost $3.92 (32%) to $8.45 on Monday after reporting that only one of 48 evaluable patients receiving tamibarotene (SY-1425) as monotherapy achieved a complete response in a Phase II trial to

Read the full 352 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers